The EMPA-FIT Study

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
Epistemonikos ID: d39f34a7f7e0b1efb15a21541510a0d92e958317
First added on: Mar 01, 2025